Literature DB >> 35403472

Gastric Xanthomatosis Secondary to Lipoprotein X in Primary Biliary Cholangitis.

Erin Petrie1, Nicholas A Hoppmann1, C Mel Wilcox1, Sameer Al Diffalha1, Meagan E Gray1.   

Abstract

Primary biliary cholangitis (PBC) is a rare autoimmune disease characterized by intralobular bile duct destruction. Patients typically present with generalized symptoms including fatigue and pruritis, and less commonly, manifestations of lipid deposition including xanthomas and xanthelasmas. We report a case of a 31-year-old female with PBC-associated cirrhosis who had cutaneous xanthelasmas and diffuse gastric xanthomas secondary to hyperlipidemia and lipoprotein X that completely resolved following liver transplantation. While gastric xanthomas have been reported in patients with PBC previously, to our knowledge, this is the first case report of diffuse gastric xanthomas secondary to PBC reported to resolve following liver transplantation, suggesting that liver transplantation is curative for gastric xanthomatosis in patients with PBC-related cirrhosis.

Entities:  

Keywords:  AMA—antimitochondrial antibody; LCAT—lecithin-cholesterol-acyl-transferase; LDL—low-density lipoprotein; Lp-X—lipoprotein X; PBC—primary biliary cholangitis

Mesh:

Substances:

Year:  2022        PMID: 35403472      PMCID: PMC9006355          DOI: 10.1177/23247096221089488

Source DB:  PubMed          Journal:  J Investig Med High Impact Case Rep        ISSN: 2324-7096


Introduction

Primary biliary cholangitis (PBC) is characterized by progressive immune-mediated destruction of intralobular bile ducts leading to cholestasis and eventually fibrosis. It typically presents in middle-aged females with fatigue and pruritis. On physical exam, hyperpigmentation is common while xanthelasmas and xanthomas are present in less than 10% of patients. Laboratory testing most often reveals a cholestatic pattern of liver injury, with particularly elevated alkaline phosphatase and positive antimitochondrial antibody (AMA) testing. AMA is positive in 95% of patients with PBC and is sufficient for diagnosis when found in conjunction with elevated alkaline phosphatase although liver biopsy can be performed as well. Hyperlipidemia is found in most patients although is not associated with increased atherosclerotic risk. We present a patient with profound dermatologic and gastric manifestations of hyperlipidemia secondary to PBC and lipoprotein X (Lp-X) who experienced complete resolution following liver transplantation.

Case Presentation

A previously healthy 31-year-old female presented with a 1-month history of jaundice. She had recently undergone cholecystectomy without improvement. In addition to jaundice and extreme fatigue, she endorsed xerostomia and unintentional weight loss secondary to early satiety. Physical exam revealed scleral icterus, hepatomegaly, and xanthelasmas, most striking on the hands (Figure 1) and around the eyes. Laboratory evaluation was significant for total bilirubin 7.8 mg/dL, aspartate aminotransferase 80 units/L, alanine aminotransferase 57 units/L, and alkaline phosphatase 1028 units/L. Total cholesterol was 1168 mg/dL and low-density lipoprotein (LDL) was measured as greater than 1200 mg/dL. Subsequent lipoprotein metabolism assay revealed the presence of Lp-X, which was mistakenly identified as LDL on initial testing. The serum AMA was positive (1:320) and florid duct lesions and nodule formation on liver biopsy confirmed a diagnosis of primary biliary cholangitis and cirrhosis.
Figure 1.

Xanthelasmas on hands of patient at initial presentation.

Xanthelasmas on hands of patient at initial presentation. An esophagogastroduodenoscopy (performed for variceal screening) revealed xanthomas coating the gastric mucosa (Figures 2 and 3), which were confirmed by hematoxylin and eosin (H&E) staining on histopathology (Figure 4). The patient had no response to ursodeoxycholic acid and was subsequently listed for liver transplantation for worsening Model for End-Stage Liver Disease (MELD) score. At 2 months following transplantation, she achieved complete resolution of cutaneous as well as gastric xanthomas, verified with endoscopy.
Figure 2.

Gastric xanthomas on endoscopy.

Figure 3.

Close-up gastric xanthomas on endoscopy.

Figure 4.

Foamy histiocytes within the lamina propria consistent with xanthoma (hematoxylin and eosin stain).

Gastric xanthomas on endoscopy. Close-up gastric xanthomas on endoscopy. Foamy histiocytes within the lamina propria consistent with xanthoma (hematoxylin and eosin stain).

Discussion

Jaundice and xanthomas are late manifestations of PBC. Xanthelasmas and xanthomas arise secondary to hypercholesterolemia and are typically found surrounding the eyelids and on the palms. Gastric xanthomas are most often singular, and a small number of case reports have described gastric xanthomas in conjunction with Helicobacter pylori infection. Gastric xanthomatosis in a patient later diagnosed with H pylori and PBC has been described. Although hypercholesteremia is present in most patients diagnosed with PBC and responsible for xanthelasmas and xanthomas, it alone does not place patients at higher risk for atherosclerotic events.[5,6] Lp-X is often largely responsible for the significant elevations of cholesterol demonstrated in patients with PBC. Lp-X is an abnormal lipoprotein made up of phospholipids and unesterified cholesterol found in the plasma of patients with cholestasis, lecithin-cholesterol-acyl-transferase (LCAT) deficiency or following lipid infusion. It is often erroneously measured as LDL by ultracentrifugation due to similar densities of the molecules. Lp-X has anti-atherogenic properties by reducing LDL oxidation and preserving endothelial homeostasis. Unlike other lipoproteins, it does not contain Apolipoprotein B100 and lacks micellar structure. High Lp-X levels have been demonstrated in patients with various cholestatic liver diseases, including viral and drug-induced hepatitis and obstructive cholestasis, in addition to PBC. This is suspected to cause plasma hyperviscosity or planar xanthomata, which rapidly improves following resolution of cholestasis. In severe cases, plasmapheresis to rapidly remove Lp-X can be considered, but treating the underlying etiology of cholestasis is recommended as definitive management. Ursodeoxycholic acid is the mainstay of treatment for PBC as it has been shown to lead to both improvement in cholestasis and modification of cholesterol metabolism. Clinical trials have demonstrated it can slow progression of disease and reduce sequelae of cirrhosis.[12,13] In patients without decompensated liver disease, obeticholic acid can be used in conjunction with ursodeoxycholic acid or as monotherapy. When patients present late in the disease stage, pharmaceutical therapy is often unsuccessful and liver transplantation is required. Hyperlipidemia and associated xanthomas and xanthelasmas of the skin are often seen to resolve posttransplantation. To our knowledge, this is the first case report of diffuse gastric xanthomas secondary to PBC reported to resolve after liver transplantation, suggesting that liver transplantation is curative for gastric xanthomatosis in patients with PBC-related cirrhosis.
  13 in total

1.  The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.

Authors:  C Corpechot; F Carrat; A M Bonnand; R E Poupon; R Poupon
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

3.  Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis.

Authors:  Dineo V Phatlhane; Annalise E Zemlin
Journal:  Ann Hepatol       Date:  2015 Nov-Dec       Impact factor: 2.400

Review 4.  Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.

Authors:  Alexey Sorokin; Jennifer L Brown; Paul D Thompson
Journal:  Atherosclerosis       Date:  2007-01-22       Impact factor: 5.162

5.  Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis.

Authors:  K D Lindor; R A Jorgensen; T M Therneau; M Malinchoc; E R Dickson
Journal:  Mayo Clin Proc       Date:  1997-12       Impact factor: 7.616

6.  Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation.

Authors:  Po-Yuan Chang; Shao-Chun Lu; Ta-Chen Su; San-Fang Chou; Wen-Huei Huang; Joel D Morrisett; Chu-Huang Chen; Chiau-Suong Liau; Yuan-Teh Lee
Journal:  J Lipid Res       Date:  2004-08-16       Impact factor: 5.922

Review 7.  Primary biliary cirrhosis.

Authors:  Elizabeth J Carey; Ahmad H Ali; Keith D Lindor
Journal:  Lancet       Date:  2015-09-11       Impact factor: 79.321

8.  Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis.

Authors:  Susanne Heimerl; Alfred Boettcher; Harald Kaul; Gerhard Liebisch
Journal:  Biochim Biophys Acta       Date:  2016-04-22

9.  Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study.

Authors:  Masoud Solaymani-Dodaran; Guruprasad P Aithal; Tim Card; Joe West
Journal:  Am J Gastroenterol       Date:  2008-08-27       Impact factor: 10.864

10.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.